Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia

2004 ◽  
Vol 70 (2-3) ◽  
pp. 331-342 ◽  
Author(s):  
J EVANS
2007 ◽  
Vol 23 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Steven P. Cohen ◽  
Robert W. Hurley ◽  
Paul J. Christo ◽  
James Winkley ◽  
Meraj M. Mohiuddin ◽  
...  

2019 ◽  
Vol 112 (3) ◽  
pp. e403 ◽  
Author(s):  
Sarita Sonalkar ◽  
Nathanael C. Koelper ◽  
Mitchell D. Creinin ◽  
Jessica M. Atrio ◽  
Mary D. Sammel ◽  
...  

2003 ◽  
Vol 84 (2) ◽  
pp. 161-167 ◽  
Author(s):  
Brick Johnstone ◽  
Ron Vessell ◽  
Thomas Bounds ◽  
Sue Hoskins ◽  
Ashley Sherman

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Laura Mühl ◽  
Emily Becker ◽  
Tanja M. Müller ◽  
Raja Atreya ◽  
Imke Atreya ◽  
...  

Abstract Background Vedolizumab has become a standard treatment for the inflammatory bowel diseases ulcerative colitis (UC) and Crohn’s disease (CD). However, there is an ongoing debate on the ideal individual treatment algorithms and means to predict treatment response are not routinely established. Aims We aimed to describe our experiences with vedolizumab at a large German tertiary referral center and to identify clinical predictors of success of vedolizumab treatment. Methods We performed a retrospective single-center cohort study employing univariable and multivariable analyses as well as Kaplan–Meier analyses of persistence on treatment. Results 36% and 35% of the patients with UC and CD, respectively, reached clinical remission after 17 weeks. Patients with lower clinical disease activity were more likely to achieve remission. The median persistence on treatment was 33 months for UC and 29 months for CD. Conclusion Our study confirms that vedolizumab is an efficient option for the treatment of UC and CD. Clinical parameters of disease activity may help to predict the success of treatment.


ASHA Leader ◽  
2017 ◽  
Vol 22 (2) ◽  
pp. 18-19
Author(s):  
Laura Smith-Olinde ◽  
Steven E. Boone

2006 ◽  
Vol 175 (4S) ◽  
pp. 378-378
Author(s):  
Adonis Hijaz ◽  
Courtenay K. Moore ◽  
Shikha Sharma ◽  
Tara L. Frenkl ◽  
Angelo A. Baccala ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document